MTNB

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Matinas BioPharma (MTNB – Research Report), with a price target of $3.00. The company's shares closed last Tuesday at $0.87. According to TipRanks.com, McCarthy 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -29.4% and a 15.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Lineage Cell Therapeutics, and Monopar Therapeutics Inc. Matinas BioPharma has an analyst consensus of Strong Buy, with a price target consensus of $3.00, representing a 206.1% upside. In a report released yesterday, H.C.
https://www.tipranks.com/news/blurbs/matinas-biopharma-mtnb-receives-a-buy-from-maxim-group?utm_source=advfn.com&utm_medium=referral